Literature DB >> 19358281

Aryl hydrocarbon receptor activation and overexpression upregulated fibroblast growth factor-9 in human lung adenocarcinomas.

Chien-Kai Wang1, Han Chang, Po-Hung Chen, Jinghua Tsai Chang, Yu-Chun Kuo, Jiunn-Liang Ko, Pinpin Lin.   

Abstract

We had previously reported that aryl hydrocarbon receptors (AhRs) are overexpressed in lung adenocarcinomas. Benzo[a]pyrene (BaP), an AhR agonist, increased FGF-9 expression in human lung adenocarcinoma cells. Similarly, several AhR agonists increased FGF-9 mRNA levels, and BaP-induced FGF-9 expression was prevented by cotreatment with AhR antagonist in human lung adenocarcinoma cells. Furthermore, AhR agonists increased transcriptional activity of FGF-9 promoter. Modulation of AhR expression via RNA interference or transient overexpression respectively reduced or increased both constitutive and BaP-induced FGF-9 expression in human lung cells. These results suggested that AhR activation and overexpression increased FGF-9 expression in lung cells. FGF-9 increased growth of lung fibroblasts but not that of lung adenocarcinoma cells. However, conditioned media collected from FGF-9-treated fibroblasts increased cell growth of lung adenocarcinoma cells. Furthermore, lung adenocarcinoma cells expressed FGF receptor 2 and cotreatment with anti-FGF receptor 2 prevented the interaction between fibroblasts and tumor cells. It is likely that FGF-9-stimulated fibroblasts secreted unknown factors, which activated FGF receptor 2 and subsequently promoted growth of lung adenocarcinoma cells. We further compared AhR and FGF-9 expression in 146 non-small cell lung cancer (NSCLC) cases by immunohistochemistry. FGF-9 expression was more common in adenocarcinomas than in squamous cell carcinomas. Furthermore, FGF-9 and AhR expression were well correlated in lung adenocarcinomas. These results suggest that AhR expression correlated positively with FGF-9 expression in lung adenocarcinomas, which might promote tumor growth by modulating communication between tumor cells and fibroblasts. Preventing AhR overexpression or disturbing FGF-9 function may reduce the development of lung adenocarcinomas. (c) 2009 UICC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19358281     DOI: 10.1002/ijc.24348

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

Review 1.  Aryl hydrocarbon receptor ligands in cancer: friend and foe.

Authors:  Iain A Murray; Andrew D Patterson; Gary H Perdew
Journal:  Nat Rev Cancer       Date:  2014-12       Impact factor: 60.716

2.  Buprenorphine, Norbuprenorphine, R-Methadone, and S-Methadone Upregulate BCRP/ABCG2 Expression by Activating Aryl Hydrocarbon Receptor in Human Placental Trophoblasts.

Authors:  Naveen K Neradugomma; Michael Z Liao; Qingcheng Mao
Journal:  Mol Pharmacol       Date:  2016-12-14       Impact factor: 4.436

3.  Upregulation of ABCG2 by romidepsin via the aryl hydrocarbon receptor pathway.

Authors:  Kenneth K W To; Robert Robey; Zhirong Zhan; Lois Bangiolo; Susan E Bates
Journal:  Mol Cancer Res       Date:  2011-02-25       Impact factor: 5.852

Review 4.  Role of AhR in positive regulation of cell proliferation and survival.

Authors:  Jiuheng Yin; Baifa Sheng; Yuan Qiu; Kunqiu Yang; Weidong Xiao; Hua Yang
Journal:  Cell Prolif       Date:  2016-08-14       Impact factor: 6.831

Review 5.  Role of the aryl hydrocarbon receptor in carcinogenesis and potential as a drug target.

Authors:  Stephen Safe; Syng-Ook Lee; Un-Ho Jin
Journal:  Toxicol Sci       Date:  2013-06-14       Impact factor: 4.849

6.  Rapid induction of lung adenocarcinoma by fibroblast growth factor 9 signaling through FGF receptor 3.

Authors:  Yongjun Yin; Tomoko Betsuyaku; Joel R Garbow; Jinbai Miao; Ramaswamy Govindan; David M Ornitz
Journal:  Cancer Res       Date:  2013-07-18       Impact factor: 12.701

7.  Evidence for Aryl hydrocarbon Receptor-Mediated Inhibition of Osteoblast Differentiation in Human Mesenchymal Stem Cells.

Authors:  AtLee T D Watson; Rachel C Nordberg; Elizabeth G Loboa; Seth W Kullman
Journal:  Toxicol Sci       Date:  2019-01-01       Impact factor: 4.849

8.  Systemic immunity shapes the oral microbiome and susceptibility to bisphosphonate-associated osteonecrosis of the jaw.

Authors:  Shirin Kalyan; Jun Wang; Elgar Susanne Quabius; Jörn Huck; Jörg Wiltfang; John F Baines; Dieter Kabelitz
Journal:  J Transl Med       Date:  2015-07-04       Impact factor: 5.531

9.  FGF9 from cancer-associated fibroblasts is a possible mediator of invasion and anti-apoptosis of gastric cancer cells.

Authors:  Chao Sun; Hirokazu Fukui; Ken Hara; Xinxing Zhang; Yoshitaka Kitayama; Hirotsugu Eda; Toshihiko Tomita; Tadayuki Oshima; Shojiro Kikuchi; Jiro Watari; Mitsuru Sasako; Hiroto Miwa
Journal:  BMC Cancer       Date:  2015-04-30       Impact factor: 4.430

10.  Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton.

Authors:  S Mithraprabhu; T Khong; A Spencer
Journal:  Cell Death Dis       Date:  2014-03-20       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.